SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of “Moderate Buy” from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.00.

Several analysts recently issued reports on the company. Citigroup assumed coverage on SAB Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $11.00 target price on the stock. Weiss Ratings cut SAB Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Chardan Capital lifted their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Leerink Partners boosted their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. Finally, Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new position in shares of SAB Biotherapeutics during the first quarter valued at about $1,915,000. Perceptive Advisors LLC lifted its holdings in SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after buying an additional 5,628,533 shares during the period. Simplify Asset Management Inc. bought a new stake in SAB Biotherapeutics during the 4th quarter valued at approximately $779,000. AWM Investment Company Inc. bought a new stake in SAB Biotherapeutics during the 2nd quarter valued at approximately $1,462,000. Finally, Propel Bio Management LLC purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $2,442,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Trading Down 4.1%

NASDAQ:SABS opened at $3.48 on Friday. The firm has a market capitalization of $316.65 million, a P/E ratio of -2.68 and a beta of 0.53. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $3.72 and a 200 day moving average of $3.77. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). On average, research analysts predict that SAB Biotherapeutics will post -1.17 earnings per share for the current year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.